Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells
Author(s)
Author(s)
Pan, X.
Hartley, J. M.
Hartley, J. A.
White, K. N.
Wang, Z.
Date Issued
2012
Publisher
Elsevier
Journal
Phytomedicine
Volume
19
Issue
7
Start page
618
End page
624
Abstract
DNA topoisomerases are nuclear enzymes that are the targets for several anticancer drugs. In this study we investigated the antiproliferative activity against human leukaemia cell lines and the effects on topoisomerase I and II of evodiamine, which is a quinazolinocarboline alkaloid isolated from the fruit of a traditional Chinese medicinal plant, Evodia rutaecarpa. We report here the anti-proliferative activity against human leukaemia cells K562, THP-1, CCRF-CEM and CCRF-CEM/C1 and the inhibitory mechanism on human topoisomerases I and II, important anti-cancer drugs targets, of evodiamine. Evodiamine failed to trap [Topo–DNA] complexes and induce any detectable DNA damage in cells, was unable to bind or intercalate DNA, and arrested cells in the G2/M phase. The results suggest evodiamine is a dual catalytic inhibitor of topoisomerases I and II, with IC50 of 60.74 and 78.81 μM, respectively. The improved toxicity towards camptothecin resistant cells further supports its inhibitory mechanism which is different from camptothecin, and its therapeutic potential.
SFU Affiliated Publication
No
Availability at SFU Library
No database links found.